Patients with atrial fibrillation, a common heart arrhythmia, have a higher risk of experiencing a stroke or blood clots. Warfarin (Coumadin) has long been the gold standard in treatment. That could be changing.

New research indicates that a person's blood type appears to influence coronary heart disease risk. Individuals with type A and B are at a higher risk, while those with rarer type AB are at the greatest risk.

A testing system commonly used to diagnose heart problems and other medical conditions has been recalled by the U.S. Food and Drug Administration.

Clot-busting drug tissue plasminogen activator ( tPA ) is the only approved treatment for dissolving blood clots common during stroke, heart attacks or pulmonary embolisms.

Patients who refuse blood transfusions when undergoing heart surgery do not appear to be at an added risk of complications following the procedure.

United States Food and Drug Administration officials today delayed approval of Eliquis ( apixaban ) to prevent stroke or systemic embolism in patients with a common heart arrhythmia for the second time.

An investigational drug appears to offer significant improvements for patients with peripheral artery disease (PAD), a recent trial found.

The practice of blood-letting or bleeding patients was abandoned in the 19th  century when it became clear there was little benefit. New research suggests the barbaric-sounding practice could offer a very real heart benefit.

Following a close vote, a U.S. Food and Drug Administration panel has declined to recommend r ivaroxaban ( Xarelto ) to treat acute coronary syndrome.

After certain types of heart attacks, doctors often use stents to prop open the arteries. Another method that may be used involves removing blood clots through thrombus aspiration (TA), but studies have shown mixed long-term results.